Neuronet - Efficiently Networking European Neurodegeneration Research

          Newsletter 6 - February 15, 2021

Welcome to the sixth
issue of the Neuronet newsletter! 

We hope this newsletter finds you well. This sixth newsletter issue provides you with up-to-date insights on the Innovative Medicines Initiative’s (IMI) research efforts to tackle challenges in neurodegeneration.

Although COVID-19 has had world-wide implications on research, it is very impressive to see how well projects keep on progressing. On that matter, we were very happy to launch the Neuronet Knowledge Base at the beginning of February, providing you with a comprehensive overview of the fantastic outputs the projects have been generating.

Apart from providing you with project updates, we also interviewed Clint Hansen from the Mobilise-D consortium as part of our spotlight on early-career investigators.

At the bottom of this newsletter you will find a link to the videos of our event on working together to address common challenges for European neurodegeneration research, that was recorded as part of the Alzheimer Europe conference. Do check them out and make sure to subscribe to our YouTube channel.

Happy reading and stay safe!

Carlos Díaz
Neuronet Project Coordinator
Research Management Partners
Lennert Steukers
Neuronet Project Leader
Associate Director,
Clinical Scientist, Janssen Pharmaceutica NV



Spotlight on early-career investigators: a Neuronet interview with Clint Hansen

We spoke to Clint Hansen who is working towards the technical validation of a sensor algorithm that will enable accurate assessment of the mobility of participants in the Mobilise-D clinical study.
Read more



Neuronet launches Knowledge Base

The Knowledge Base brings together key information about the various projects of the IMI ND portfolio. This comprehensive resource is an integral part of our endeavour to boost collaboration across the research portfolio by assisting in identifying gaps, multiplying the portfolio’s impact, and enhancing its visibility with related initiatives in Europe and worldwide.
Read more

IDEA-FAST project progress update

Although COVID-19 restrictions had their implications, Consortium members have been busy adapting to the new situation and developing alternative plans. Here we provide you with a high-level overview of their recent activities and achievements.
Read more

European Medicines Agency supports Mobilise-D to pursue the qualification of Digital Mobility Outcomes as biomarkers

In 2019, the Mobilise-D consortium requested qualification advice for Digital Mobility Outcomes (DMOs) at the European Medicines Agency. This initial qualification is part of the Mobilise-D’s wider objective to establish acceptable DMOs (derived from suitable mobile wearable devices and associated algorithms) as biomarkers for clinical benefit (i.e., as surrogate, primary or key secondary endpoints) in pivotal clinical trials for treatment of diseases or health conditions that impact upon mobility.
Read more

IDEA-FAST and Mobilise-D join forces to strengthen research and development of digital biomarkers

From January 2021 onwards, two EU Innovative Medicines Initiatives, IDEA-FAST and Mobilise-D, will join forces to increase the impact and the benefits of digital health technologies developed by both projects.
Read more

The final EPAD dataset is now available to the entire research community

The European Prevention of Alzheimer’s Dementia (EPAD) project is very pleased to announce the external release of its final dataset for all researchers from over the world. The final dataset is called Version.IMI (V.IMI) as it represents all the data collected and processed during the IMI period of EPAD.
Read more

AMYPAD project announces end of recruitment in the Diagnostic and Patient Management Study

At the end of 2020, the members of the AMYPAD project announced the completion of the enrolment of research participants in its Diagnostic and Patient Management Study. In this randomised clinical study, participants with possible Alzheimer’s disease were included to determine the usefulness of β-amyloid imaging as a diagnostic marker for dementia.
Read more

RCSI STEM careers promotion talks present
PD-MitoQUANT to young people

Midlands Science partnered with Helena Bonner, a Neuroscientist at the Royal College of Surgeons in Ireland, as well as an Outreach officer at the Centre for Systems Medicine, RCSI to provide informative virtual talks for a number of schools across the Midlands for College Awareness Week.
Read more

RADAR-CNS Epilepsy Study 2 begins recruitment

The RADAR-CNS Epilepsy Study team based at King’s College London recruited their first participants to Study 2. The Study 2 participants are asked to wear a wrist-worn device to measure various parameters including movement and heart rate. Their stress, mood and sleep will also be monitored with some active apps downloaded on mobile devices.
Read more

AETIONOMY & EPAD researchers launch AData(Viewer) an online tool to explore the Dataset Landscape in Alzheimer's Disease

To assess the Alzheimer's disease data landscape, Colin Birkenbihl and colleagues analysed datasets from 9 cohort studies, including the EMIF-1000 and EPADv1500 studies. Summarising the data parameters and describing how they overlap between studies, they observed fairly large biases towards high levels of education and, in particular, a strong bias towards white/Caucasian ethnicity. All the analyses reported in the article have been made available through “ADataViewer”, an interactive web application developed by Fraunhofer SCAI that displays the findings in data availability maps.
Read more



Presentations from annual Neuronet event at the Alzheimer Europe conference are now online

This year, we expanded the focus of the event, titled "Working together to address common challenges for European neurodegeneration research". Over the course of four parallel sessions, we showcased the work of IMI neurodegeneration projects on data sharing, ethics and regulatory/HTA interactions, and hosted presentations from early-career investigators working on these projects. In addition, we held a roundtable discussion, during which project leaders discussed the challenges experienced by public-private partnerships during the COVID-19 pandemic, and how research will evolve in the critical post-COVID period.
Read more

Neuronet project newsletters

Remote Assessment of Disease and Relapse – Alzheimer’s Disease
January 2021 (RADAR-AD)
This issue includes a spotlight on RADAR-AD researcher Sébastien Libert who shared findings from ethics interviews with members of the Patient Advisory Board.
A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease
January 2021 (PD-MitoQUANT)
This newsletter provides a recap of the ParkinsonsUK Virtual Research Conference and a Partner Spotlight on GeneXplain among other interesting updates.
Remote Assessment of Disease and Relapse – Central Nervous System
January 2021 (RADAR-CNS)
This issue includes an immersive performance based on the RADAR-CNS study, investigating how wearable technologies & mobile phones can track and help prevent depression, epilepsy and multiple sclerosis.
Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement
December 2020 (Mobilise-D)
In the latest Mobilise-D newsletter, the consortium looks back at the its activities during 2020 and the milestones it achieved.
Amyloid imaging to prevent Alzheimer's disease Newsletter
December 2020 (AMYPAD)
In this issue, you will find an interview with two AMYPAD collaborators, the highlighted achievements over the past quarter as well as AMYPAD’s participation in relevant events.

What we are reading

Identifying digital endpoints to assess fatigue, sleep and activities in daily living in neurodegenerative disorders and immune-mediated inflammatory diseases Blog
January 2021 (IDEA-FAST)
Two members from Parkinson Madrid emphasise the pandemic's ongoing impact on people affected by Parkinson’s & opportunities provided by technology to help manage their disease & therapies remotely.


This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821513. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK.

Any related content solely reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.

          Newsletter 6 - February 15, 2021

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
NEURONET project · 14, rue Dicks · Luxembourg 1417 · Luxembourg

Email Marketing Powered by Mailchimp